Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection

Background Early recurrence of hepatocellular carcinoma (HCC) is a major obstacle to improving the prognosis, and no widely accepted adjuvant therapy guideline for patients post-liver resection is available. Currently, all available methods and biomarkers are insufficient to accurately predict post-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Liming Zheng, Xi Gu, Guojun Zheng, Xin Li, Meifang He, Longgen Liu, Xike Zhou
Formato: article
Lenguaje:EN
Publicado: PeerJ Inc. 2021
Materias:
R
Acceso en línea:https://doaj.org/article/3e08f6c374c74528b081541cbed5fc68
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!